https://www.selleckchem.com/pr....oducts/NVP-TAE684.ht
The public transcriptomics datasets showed that the expression level of IL-6 was positively correlated with EGFR in CRC patients, and PROGgeneV2 analysis indicated that IL-6 and CD206 both predicted poor recurrence-free and overall survival of CRC patients. Furthermore, the inhibition efficacy of cetuximab was significantly attenuated in IL-6 knockout CRC mice model. These results indicate a new macrophage-based molecular mechanism explaining the effect of cetuximab in treatment of colorectal cancer. These results indicate a new macr
Like
Comment
Share
